Ozempic Dosing and Administration Guidelines

Standard Dosing Schedule

The American College of Cardiology and Mayo Clinic recommend an initial dose of 0.25 mg subcutaneously once weekly for 4 weeks, followed by a maintenance dose of 0.5 mg, with further titration to 1 mg or 2 mg as needed for glycemic control in patients with type 2 diabetes 1, 2
The maintenance dose of 0.5 mg subcutaneously once weekly can be increased to 1 mg once weekly if additional glycemic control is required after at least 4 weeks on the 0.5 mg dose, as recommended by the Mayo Clinic 1, 2, 3

The American College of Cardiology recommends no dosage adjustment for patients with renal impairment, including those with end-stage renal disease, when using Ozempic 1, 3
The American College of Cardiology suggests using Ozempic with caution in patients with severe hepatic impairment, due to limited experience in this population 2
The American College of Cardiology recommends no specific dose adjustment based on age for elderly patients using Ozempic 2

The Mayo Clinic recommends a target dose of 2.4 mg once weekly for weight management in patients with obesity or overweight and at least one weight-related comorbidity 1, 4

Gradual dose titration is essential to minimize gastrointestinal adverse effects, as recommended by medical guidelines, with a strength of evidence based on clinical trials 5

The purpose of the initial phase is to allow GI tolerance to develop, according to Gastroenterology guidelines 6
For patients using semaglutide for obesity or weight management, the target maintenance dose of 2.4 mg weekly is reached after 16 weeks, as recommended by Gastroenterology guidelines 6
If more than 2 consecutive doses are missed, clinical judgment is required, and if the patient tolerated the medication well previously, resuming at the same dose can be considered, as suggested by Gastroenterology guidelines 6
If 3 or more consecutive doses are missed, consider restarting the titration schedule, according to Gastroenterology guidelines 6
Do not use Ozempic with other GLP-1 receptor agonists or DPP-4 inhibitors, as recommended by Gastroenterology guidelines 6
When using Ozempic with insulin or sulfonylureas, monitor closely for hypoglycemia and adjust doses as needed, according to Gastroenterology guidelines 6
Ozempic may delay gastric emptying and impact absorption of oral medications requiring rapid onset, as noted by Gastroenterology guidelines 6
Some patients achieve adequate response at submaximal doses and can continue that dose long-term rather than escalating, as suggested by Gastroenterology guidelines 6